ArticleNaunyn-Schmiedeberg's archives of pharmacology2020
Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- A systematic review and pharmacovigilance analysis of the risk of agranulocytosis associated with metamizole use.Scientific reports · 2025Pooled it
- Safety of metamizole (dipyrone) for the treatment of mild to moderate pain-an overview of systematic reviews.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- Metamizole-induced agranulocytosis from a German intensive care perspective.Frontiers in medicine · 2026Article
- Metamizole: Indications and Risks.Deutsches Arzteblatt international · 2026Review
- Dipyrone use in Brazil: clinical conditions, sociodemographic characteristics, population attitudes and perceptions.Cadernos de saude publica · 2026Article
- Learning From the Uncommon in Common Practice: A Case Report on Metamizole-Induced Agranulocytosis.Cureus · 2025Article
- [Metamizole / dipyrone in psychiatry - What about the pharmacokinetics?]Der Nervenarzt · 2025Review
- Discovery of Pyrazoline Benzenesulfonamide Derivatives as Anticancer Agents: A Review.Drug design, development and therapy · 2025Review
- Risk of agranulocytosis with metamizole in comparison with alternative medications based on health records in Spain.European journal of clinical pharmacology · 2024Article
- Significant neutropenia induced by metamizole dependent neutrophil antibodies.Blood transfusion = Trasfusione del sangue · 2024Article
- Assessing potential risk factors for metamizole-induced leukopenia.Therapeutic advances in drug safety · 2024Article
- Antithyroid drug-induced leukopenia and G-CSF administration: a long-term cohort study.Scientific reports · 2023Article
- Metamizole-induced agranulocytosis (MIA): a mini review.Molecular and cellular pediatrics · 2023Review
- Parenteral Ready-to-Use Fixed-Dose Combinations Including NSAIDs with Paracetamol or Metamizole for Multimodal Analgesia-Approved Products and Challenges.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Case Report: Simultaneously Induced Neutropenia and Hemolysis After a Single Metamizole Dose.Drugs in R&D · 2023Article
- Article
- Pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery.PloS one · 2022Article
- The antipyretic effectiveness of dipyrone in the intensive care unit: A retrospective cohort study.PloS one · 2022Article
- Metamizole Use in Children: Analysis of Drug Utilisation and Adverse Drug Reactions at a German University Hospital between 2015 and 2020.Paediatric drugs · 2022Article
- Drug-Induced Neutropenia During Treatment of Non-Neoplastic Dermatologic Diseases: A Review.Clinical drug investigation · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The non-opioid analgesic metamizole (dipyrone) is used for the treatment of acute and chronic pain and fever. Agranulocytosis is known as a serious adverse drug reaction of metamizole with potentially fatal outcome. However, its frequency is controversially discussed. The aim of our study was to determine the risk of metamizole-associated agranulocytosis and neutropenia using statutory health insurance data. We analyzed data from a large German health insurance fund in the period from 2010 to 2013. Metamizole-exposed subjects were identified and compared to a propensity score-matched control cohort. A total of 630,285 metamizole-treated subjects and 390,830 matched control subjects were included. In the metamizole cohort, ICD codes for agranulocytosis and neutropenia appeared more often than in non-users. The relative risk for drug-induced agranulocytosis and neutropenia (D70.1) was 3.03 (95% confidence interval, 2.49 to 3.69). The risk for developing drug-induced agranulocytosis and neutropenia after metamizole prescription was 1: 1602 (CI 95%, 1:1926 to 1:1371). Our results confirm the risk estimation of previous studies. However, the outcome of our study may be confounded by an association of metamizole treatment and chemotherapy. Therefore, consequences for treatment have to be drawn with care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.